AbbVie Inc (ABBV) : Adell Harriman Carpenter Inc scooped up 125 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 101,915 shares of AbbVie Inc which is valued at $6.3 Million.AbbVie Inc makes up approximately 1.72% of Adell Harriman Carpenter Inc’s portfolio.
Other Hedge Funds, Including , Gsa Capital Partners Llp reduced its stake in ABBV by selling 15,325 shares or 61.95% in the most recent quarter. The Hedge Fund company now holds 9,412 shares of ABBV which is valued at $583,544. AbbVie Inc makes up approx 0.04% of Gsa Capital Partners Llp’s portfolio.Guardian Investment Management reduced its stake in ABBV by selling 2,000 shares or 8.26% in the most recent quarter. The Hedge Fund company now holds 22,216 shares of ABBV which is valued at $1.4 Million. AbbVie Inc makes up approx 1.58% of Guardian Investment Management’s portfolio. Point View Wealth Management added ABBV to its portfolio by purchasing 4,455 company shares during the most recent quarter which is valued at $278,482. AbbVie Inc makes up approx 0.18% of Point View Wealth Management’s portfolio.Bryn Mawr Trust Co reduced its stake in ABBV by selling 555 shares or 1.17% in the most recent quarter. The Hedge Fund company now holds 46,993 shares of ABBV which is valued at $2.9 Million. AbbVie Inc makes up approx 0.19% of Bryn Mawr Trust Co’s portfolio.Compton Capital Management Inc Ri reduced its stake in ABBV by selling 350 shares or 1.17% in the most recent quarter. The Hedge Fund company now holds 29,440 shares of ABBV which is valued at $1.8 Million. AbbVie Inc makes up approx 1.05% of Compton Capital Management Inc Ri’s portfolio.
AbbVie Inc opened for trading at $61.91 and hit $62.62 on the upside on Monday, eventually ending the session at $62.45, with a gain of 0.73% or 0.45 points. The heightened volatility saw the trading volume jump to 67,07,435 shares. Company has a market cap of $101,004 M.
On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.